Hamill John P.

Hamill John P. is listed in filings as SrVP/CFO/Prin Fin & Acct Ofcr at Aprea Therapeutics, Inc.. This profile follows SEC Form 4 activity through Apr 1, 2026, including purchase activity. Recent filings connect the profile to Aprea Therapeutics, Inc. (APRE). The current snapshot covers public activity from Oct 15, 2024 to Apr 1, 2026. Reported amounts are shown as $31 to $30.9K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.